Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.
Authors
Mary Frances Mulcahy
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;
Mary Frances Mulcahy , Halla Nimeiri , Osama E. Rahma , Jonathan Wills , Kristian Del Rosario , Justin Lien , Raphael Pelossof , Talal Ahmed , Justin Guinney , Nike Beaubier , Filippo Pietrantonio , Yoshiaki Nakamura , Iker Huerga , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 326)
DOI
10.1200/JCO.2023.41.4_suppl.326
Abstract #
326
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
First Author: Samuel J Klempner
Poster
2022 ASCO Gastrointestinal Cancers Symposium
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
First Author: Samuel J Klempner
Poster
2021 ASCO Annual Meeting
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).
First Author: Samuel J Klempner
Poster
2020 ASCO Virtual Scientific Program
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2–advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
First Author: Manish A. Shah